Ревалгин is a combination medicine that is commonly used across therapeutic domains where a mix of symptomatic support for physical discomfort and tension-related symptoms is needed. It may assist with addressing symptom clusters that create noticeable functional strain, particularly those associated with symptoms of increased neurological or muscular activity.

---

What Ревалгин treats: main uses and benefits

The active ingredients in Revalgin provide combined support that is relevant for easing symptoms related to physical discomfort and increased neurological or muscular activity. The medicine is applied across domains to help manage symptoms related to physical discomfort and fever that may be temporarily intense, and may also assist with relief of symptoms of increased neurological or muscular activity.

It is considered relevant in situations involving recurrent or episodic manifestations. It helps address symptoms linked to organ-specific functional stress and inflammatory or irritative states, such as symptoms linked to organ-specific functional stress that create noticeable physiological strain, as well as symptoms related to physical discomfort that become more disruptive during flare-ups.

---

Quick Fact: Relief for Tension-Related Symptoms

The medicine provides supportive relief when symptoms interfere with routine activities, which supports the patient during difficult episodes by easing distress and maintaining functional stability.

Regulatory References

1. European Medicines Agency (EMA) review

The eligibility profile for Ревалгин is defined by mandatory restrictions and formal contraindications documented in regulatory sources, limiting its use to specific populations who do not present with certain physiological conditions.

Eligibility Status

Classification	Populations Covered
Allowed	Adults and adolescents 15 years of age and older who are free of listed contraindications.
Contraindicated	Individuals with known hypersensitivity to the active substances (e.g., metamizole) or other pyrazolone derivatives/NSAIDs.
Contraindicated	Patients with severe, pre-existing hepatic (liver) or renal (kidney) failure or impairment.
Contraindicated	Individuals with hematopoietic disorders (e.g., bone marrow suppression, agranulocytosis) or specific enzyme deficiencies (glucose-6-phosphate dehydrogenase).
Contraindicated	Individuals with pre-existing conditions like closed-angle glaucoma, certain severe gastrointestinal conditions, or specific cardiovascular diseases (e.g., severe heart failure).
Contraindicated	Pregnancy (especially the third trimester) and lactation (breastfeeding).

Official regulatory documents establish these contraindications as absolute prohibitions, legally defining the groups who must not use the medicine. Eligibility is therefore restricted to individuals who meet the minimum age requirement and do not have any of the specific severe concurrent diseases or hypersensitivities listed in the official labeling.

Interactions with other medicines and products

The interaction profile for Ревалгин, primarily driven by its Sodium Metamizole component, is characterized by enzyme-mediated pharmacokinetic interactions and specific pharmacodynamic risks documented in regulatory labels.

---

Formal Prohibitions and Exposure-Altering Interactions

Co-administration with Methotrexate is strictly prohibited in official documents due to the risk of increased Methotrexate exposure and potential toxicity. Additionally, use with Chlorpromazine is restricted because of the documented risk of inducing severe hypothermia.

Metamizole is an official inducer of the enzyme CYP2B6, which leads to a clinically significant reduction in the plasma concentrations of certain co-administered medicines, resulting in decreased therapeutic exposure. Agents affected by this include the antiretroviral Efavirenz and the antidepressant Bupropion.

---

Required Monitoring and Potentiation

Regulatory documents mandate specific precautions for narrow therapeutic index drugs. Co-administration with the immunosuppressants Ciclosporin and Tacrolimus is documented to reduce their plasma levels. This effect requires close clinical monitoring of plasma concentration and potential adjustment of their dosage.

In terms of pharmacodynamic effects, the official label notes a mutual potentiation of effects when taken with alcohol/ethanol. Furthermore, the presence of Fenpiverinium Bromide can lead to the potentiation of effects when combined with other anticholinergic agents.

Central Mechanism: Pain and Thermoregulation

This mechanism involves the action of Metamizole, which primarily operates in the Central Nervous System (CNS) by functioning as an inhibitor of the enzyme Cyclooxygenase-3 ( COX-3). This interaction reduces the synthesis of pain- and fever-associated prostaglandins in the brain, resulting in an analgesic and antipyretic physiological effect.

---

Dual-Action Peripheral Spasmolysis

This mechanism involves the two distinct spasm-modulating components, Pitofenone and Fenpiverinium bromide, which target smooth muscle in the viscera. Fenpiverinium blocks nerve signals through anticholinergic action on muscarinic receptors. Pitofenone directly decreases muscle contractility by affecting Ca^2+ channels through musculotropic action. The result is a significant reduction in smooth muscle tone and contractility, thereby reducing the magnitude of the smooth muscle spasm.

---

Synergistic Effect on Muscular Hyperactivity Pathways

The drug is designed to achieve a three-way synergy, where the central analgesic mechanism of Metamizole is combined with the dual-pathway peripheral spasmolysis. This concurrent action targets both the central sensory processing and the peripheral muscular hyperactivity.

The administration of Ревалгин is defined by official instructions that govern the approved routes, dosing schedules, and duration of use. The medication is authorized in two distinct forms: tablets for the oral route and a solution for injection intended for parenteral administration, which may be intramuscular (IM) or slow intravenous (IV) injection, as outlined in the official labeling.

Administration Routes and Standard Schedules

Route	Administration Principle	Adult Frequency
Oral	Tablets are to be taken after a meal with water.	Up to three times daily (2–3 times/24 hours).
Parenteral	Reserved for acute, severe episodes under medical supervision.	May be repeated after 6 to 8 hours if medically necessary.

For oral use, the standard unit dose for adults and adolescents (over 15 years) is typically one to two tablets per administration. The injectable solution is administered as 2 to 5 mL per unit dose. The official protocol limits the treatment to short-term symptomatic use; for example, the oral form should generally not exceed three to five consecutive days.

Contextual and Population Adjustments

Specific procedural instructions exist for proper administration. If the solution for injection is administered intravenously, the official protocol mandates a slow infusion rate—typically lasting at least five to eight minutes—and must occur in a setting prepared for potential medical intervention. Furthermore, dose adjustments are officially stipulated for certain populations. Patients with known renal or hepatic impairment, as well as older adults whose kidney or liver functions may be reduced, are generally directed to use lower doses of the medicine. These guidelines ensure standardized use aligned with the clearance profile of the active ingredients.

Research Evidence / Overview of Studies for Ревалгин

---

Evidence for Use in Pain Associated with Smooth Muscle Spasm (Colic)

The combination of ingredients in Ревалгин was studied for research exploring symptoms linked to smooth muscle tightening or colic. Research has explored this use primarily through observational settings and a limited number of randomized controlled trials (RCTs) focusing on combinations of similar analgesic and spasmolytic agents. These studies included adult patients experiencing acute or disruptive episodes like spasms in the digestive, bile, or urinary tracts.

The research examined outcomes related to physical discomfort, specifically how symptom intensity changed and the time interval required for the initial measured change in symptoms. Findings describe patterns observed in the studies concerning short-term measured changes during these acute phases.

Evidence for Use in Acute or Severe Pain Symptoms

The primary ingredient in Ревалгин, Sodium Metamizole, was studied for research examining various sources of acute pain, including post-operative discomfort and severe pain not necessarily related to smooth muscle spasm. This research included a high volume of randomized controlled trials (RCTs) and multicenter trials that examined adult patients with different types of pain burdens.

In these studies, researchers examined outcomes related to systemic or functional imbalance by measuring the magnitude of pain reduction compared to control groups or other standard pain relievers. The resulting data show patterns related to measured outcomes over defined time intervals. This high volume of research applies directly to Metamizole alone.

---

What is Still Uncertain About the Research for Ревалгин

The evidence landscape indicates several areas where certainty remains low. A significant gap is the lack of high-quality, dedicated trials for the specific three-way combination (Metamizole, Pitofenone, and Fenpiverinium Bromide), meaning the outcomes of the full synergistic action are not fully established.

Furthermore, comparative evidence is lacking against key existing alternatives for managing colic pain, meaning direct assessment is currently limited. Also, follow-up durations were limited in many studies, meaning outcomes for long-term effects are not fully established regarding durability of effect or patterns associated with repeated use.

Key Studies & References

1. European Medicines Agency (EMA) review on Metamizole (Art. 31 Referral)
2. Metamizole Monograph (LiverTox: Clinical and Research Information on Drug-Induced Liver Injury)

Common questions about Ревалгин (FAQ)

---

Q: Is the main active ingredient (Metamizole) considered an opioid or a narcotic?

According to official regulatory classifications, Metamizole is defined as a non-opioid analgesic. It belongs to the pyrazolone chemical class. It is classified as a non-opioid.

Q: Is this medicine only used for pain, or can it reduce fever as well?

Official product information indicates that the Metamizole component has both analgesic (pain-relieving) and antipyretic (fever-reducing) properties. The drug's profile includes addressing both pain and fever.

Q: Can Ревалгин be used by children, and if so, at what age is it appropriate?

The fixed-dose tablet form of this combination medicine is formally contraindicated for use in children under 15 years of age in its official labeling. The medicine is generally used by adults and adolescents 15 years of age and older.

Q: Does the drug cause drowsiness or affect the ability to focus?

Regulatory documents list potential adverse reactions that may affect the central nervous system. Official product information notes that caution is advised regarding tasks that require focus or high levels of alertness.

Q: What are the general expectations regarding driving or operating machinery after taking Ревалгин?

Due to the possible adverse reactions that may affect alertness or coordination, official product information describes a specific warning regarding operating machinery or driving.

Q: How is Ревалгин different from common painkillers like Ibuprofen or Paracetamol?

Ревалгин is defined as a fixed-dose combination that pairs an analgesic (pain reliever) with two separate spasmolytic (muscle-relaxing) agents. This unique formulation is specifically designed to address pain that is associated with smooth muscle spasms.

Q: Is there a risk of dependency or tolerance forming with long-term use of Ревалгин?

The official protocol limits the treatment to short-term symptomatic use, which is typically not meant to exceed three to five consecutive days. This reflects the drug's approved scope for symptomatic use.

Q: What is the evidence level or research backing the use of Ревалгин for general pain relief?

Research exists supporting the analgesic effect of Metamizole alone for acute pain. However, official information notes a lack of dedicated high-quality trials examining the outcomes of the full three-way combination.

Q: What kind of pain is Ревалгин typically prescribed or recommended for?

Official regulatory labels list indications including pain of various origin such as headache, toothache, menstrual pain, muscle pain, and pain associated with spasms of smooth muscles in the gastrointestinal or urinary tract.

Q: Can this medicine be used for both muscle pain and stomach cramps?

Regulatory indications cover relief for both muscle pain and pain caused by spasms of smooth muscles in the gastrointestinal tract (stomach cramps). The spasmolytic components are included to target this specific type of pain.

Q: Is Ревалгин considered a strong pain reliever?

The Metamizole component is officially classified as a potent analgesic (pain reliever) with spasmolytic properties. This classification is used for potent pain relievers.

Q: Is it true that this drug is restricted or banned in some countries?

Regulatory documents and authoritative health information confirm that while the drug is widely available in some regions, it has been banned or restricted in more than 30 countries. The restrictions are grounded in concerns about rare, serious adverse reactions described in regulatory safety reports.

Q: Can Ревалгин cause issues with kidney or liver function?

Regulatory documentation formally contraindicates its use in patients with severe, pre-existing liver or kidney failure. Additionally, post-marketing reports have documented risks of acute kidney injury (AKI) and drug-induced liver injury (DILI).

Q: Is it necessary to take the tablet with food or can it be taken on an empty stomach?

Official regulatory instructions explicitly direct that tablets are to be taken after a meal with water, as directed by official instructions.

Q: What is the general safety classification does the main ingredient, Metamizole, have?

Metamizole is officially classified as a Non-opioid analgesic and a pyrazolone derivative. It is recognized for its combined analgesic, antipyretic (fever-reducing), and spasmolytic (spasm-reducing) properties.

Q: Is it normal to use Ревалгин only when pain starts, or should it be taken regularly?

The official protocol limits the treatment to short-term symptomatic use. This protocol specifies its intended use for short-term, symptomatic treatment of acute pain.

Q: Is there a list of drugs that reduce the effect of Ревалгин?

Regulatory documents note a potential pharmacodynamic interaction with Acetylsalicylic acid (Aspirin) that may interfere with its anti-platelet effect.

Q: Is there a list of drugs that increase the risk of side effects from Ревалгин?

Regulatory documents strictly prohibit co-administration with Methotrexate due to the risk of increased toxicity. Furthermore, combining it with other anticholinergic agents can potentiate certain side effects of the spasmolytic components.

Q: How quickly can a patient expect the pain relief effects of Ревалгин to start working?

Official product information notes that a clear analgesic effect can generally be expected 30 to 60 minutes after oral administration. For parenteral (injection) administration, the effect typically starts in approximately 30 minutes.

Q: How long does the pain-relieving effect of one dose of Ревалгин typically last?

Official dosage instructions define the maximum interval between doses, such as every 6 to 8 hours for the injectable form. This interval represents the recommended duration for symptomatic dosing.

Q: Is the medicine available in different forms (e.g., tablets, injection, liquid)?

According to official regulatory documents, the medicine is authorized in two distinct forms: tablets for oral use and a solution for injection for intramuscular or slow intravenous administration.

Q: Can Ревалгин be used to manage pain from menstrual cramps?

Official indications for the medicine include the use for pain relief associated with menstrual cramps (dysmenorrhea).

Q: Is Ревалгин considered a treatment for inflammation or only for pain and spasms?

The official classification defines the product primarily as an analgesic and spasmolytic. Its therapeutic profile is characterized by addressing pain and muscle spasms, and it is typically not classified as a conventional Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: Can Ревалгин be taken on an 'as needed' basis for sudden pain flare-ups?

The official protocol limits the treatment to short-term symptomatic use. This protocol specifies its intended use for short-term, symptomatic treatment of acute pain episodes, rather than a preventative schedule.

Q: What is still uncertain about the research for Ревалгин?

Research summaries indicate limitations related to the availability of dedicated high-quality trials for the full three-way combination and comparative evidence against alternative treatments. Furthermore, follow-up durations are often limited regarding long-term effects.

Q: What information is available about its use in elderly patients, specifically those over 65?

Official protocols stipulate that older adults whose kidney or liver functions may be reduced are generally directed to use lower doses of the medicine. These adjustments are noted in official regulatory guidelines.

How to Store and Dispose of Ревалгин?

Official regulatory guidelines strictly define the conditions necessary to maintain the quality and safety of this combination medicine.

Storage Conditions

Requirement	Detail
Temperature	Store below 25 C
Protection	Keep protected from both light and moisture
Packaging	Must be stored in its original container

---

Safety and Disposal

The product must be kept out of the sight and reach of children. Do not use the medicine after the expiry date shown on the carton. For disposal, the product must not be thrown into wastewater or household waste. Instead, consult a pharmacist on the proper method for discarding unused or expired medication, as this ensures compliance with environmental protection regulations.